Shanghai, China, and Heidelberg, Germany – May 10, 2024 – Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced that it will present preclinical data of FL-091 (a NTSR1-targeted RDC program) in an oral presentation at the 2024 SNMMI (The Society of Nuclear Medicine and Molecular Imaging) Annual Meeting, held on June 8th to 11th, 2024 at Metro Toronto Convention Centre, Toronto, ON, Canada.

Oral Presentation Details

Title: Development of ¹⁷⁷Lu-FL-091 for the treatment of NTSR1-positive cancers

Session Title: Novel Preclinical Platforms for Therapeutic and Theranostic Applications in Oncologic Imaging

Session Type: Scientific Session

Session Date: Sunday, June 09, 2024

Session Time: 12:30 PM - 1:45 PM

Presentation Time: 1:35 PM - 1:45 PM

About FL-091

FL-091 is a novel NTSR1 targeting radionuclide drug conjugate for the treatment of NTSR1-positive cancers. ¹⁷⁷Lu-FL-091 binds to NTSR1 with high affinity to the receptor and demonstrates an excellent in vivo biodistribution profile with high tumor uptake and fast normal tissue clearance. In particular, ¹⁷⁷Lu-FL-091 shows promising in vivo efficacy in different xenograft models. Studies to investigate FL-091 conjugated to the radionuclide Actinium-225 are in progress.

About Full-Life Technologies

Full-Life Technologies Limited ("Full-Life") is a fully integrated global radiotherapeutics company with operations in Belgium, Germany, and China. We aim to own the entire value chain for radiopharmaceutical research & development, production & commercialization in order to deliver clinical impact for patients. The Company plans to attack core issues affecting radiopharmaceuticals today through innovative research that targets the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and scientists with a demonstrated track record in the life sciences, as well as radioisotope research and clinical development.

About SNMMI

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is a nonprofit scientific and professional organization that promotes the science, technology and practical application of nuclear medicine and molecular imaging. SNMMI strives to be a leader in unifying, advancing and optimizing molecular imaging, with an ultimate goal of improving human health. With 13,000 members worldwide, SNMMI represents nuclear and molecular imaging professionals, all of whom are committed to the advancement of the field. The premier educational, scientific, research, and networking event in nuclear medicine and molecular imaging, the SNMMI Annual Meeting provides physicians, technologists, pharmacists, laboratory professionals, and scientists with an in-depth view of the latest research and development in the field as well as providing insights into practical applications for the clinic.